Member Posts > Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL): A Novel Approach to Heart Failure Management
Redefining Heart Failure Care
CRD-38 is an investigational cannabidiol-based therapy designed to combat inflammation and fibrosis, the underlying causes of heart failure progression.
Why CRD-38 is Different
✔ Targets inflammation, a key driver of disease progression.
✔ Delivers consistent drug levels, ensuring maximum efficacy.
✔ Offers subcutaneous administration, improving patient adherence.
Preclinical Data Highlights
📌 BNP biomarker reduction, signaling improved heart function.
📌 Reduced fat accumulation, reducing cardiovascular strain.
📌 Strong anti-inflammatory effects, reinforcing cardioprotective benefits.
Advancing CRD-38 to Clinical Trials
✔ Ongoing pharmacokinetic studies.
✔ Regulatory safety testing in progress.
✔ Clinical trial preparations underway.
🔗 Discover More About CRD-38's Clinical Pathway:

#CardiolTherapeutics #HeartHealth #MedicalInnovation #CardiacCare #PatientStories #Myocarditis #Pericarditis #HealthcareResearch #CommunityEngagement #CannabidiolResearch #HeartDiseaseAwareness #AdvancedTherapies #CardiolRx #CRD38